Biolegend, 632252, Purified anti-human IFN-α2 Antibody, 100μg

Interferons are divided into type I, II, and III. Type I IFNs (IFN-α and IFN-β) are most abundant in number, distribution, and expression. They are also highly conserved among mammals in both structure and function. IFN-α2 has been used in the treatment of cancer such as bladder cancer, hepatocellular carcinoma, and leukemia. IFN-α2 augments the suppressed immune functions in patients with head and neck squamous cell carcinoma (HNSCC). IFN-α2 initiated T and NK cell mediated cytotoxicity of tumor cells through IFNγ dependent and independent mechanisms. IFN-α2 enhances suppressed T cell cytotoxicity by stimulation of the perforin-granzyme B system (IFNγ dependent). IFN-α2 also induces the expression of perforin-granzyme B in NK cells (NK mediated cytotoxicity, IFNγ independent). In a preliminary study, IFN-α2 appears to be an effective immunostimulator and impacts the clinical outcome in tongue squamous cell carcinoma patients. IFN-α has been used in the treatment of chronic hepatitis C (CHC); nevertheless, IFN-α is relatively unstable and requires frequent parenteral administration. Pegylation of IFN-α, polyethylene glycol (PEG)-IFN-α, reduces in vitro activity but increase the stability and plasma half-life of IFN-α. Therefore, PEG-IFN-α has replaced IFN-α in CHC treatment.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Human Recombinant IFN-α2 Protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: Direct ELISA - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by Direct ELISA. The optimal concentration of this reagent for the specific application and the experiment design should be established by the end-user.
Additional Product Notes: This product is intended for sandwich-based immunoassay development on various assay platforms requiring antibody pairs. This antibody (clone W20057G) could function as a capture antibody when paired with biotin anti-human IFN-α2 (Cat. No. 636253) (clone W21083E) or (Cat. No. 616753) (clone Poly5292) as the detection antibody and using Recombinant Human IFN-α2 protein (Cat. Nos. 592702, 592704, 592706, and 592708) as the assay standard.
RRID: AB_3662350 (BioLegend Cat. No. 632252)
Distribution: IFN-α is ubiquitously expressed
Function: IFN-α stimulates cytotoxic T lymphocytes and natural killer cell function. IFN-α has immunomodulatory and antiviral properties. IFNα2a induces CXCL10 in human microvascular endothelial cells and pulmonary artery smooth muscle cells. It is induced by viral infection.
Interaction: Varieties of cells express the IFNα receptor (IFNAR).
Ligand/Receptor: IFNAR complex has two components, IFNAR1 and IFNAR2.
Cell Type: Embryonic Stem Cells
Biology Area: Cancer Biomarkers, Neuroinflammation, Neuroscience, Stem Cells
Antigen References: Bose A and Baral R. 2007. Immunol Lett. 108:68-77. Zhao W, et al. 2008. J Immunol. 180:5483-9. Badiger R, et al. 2012. Plos One. 7:e46779. Aghemo A, et al. 2010. Nat Rev Gastroenterol Hepatol. 7:485-94. Becker-Merok A, et al. 2013. Lupus. 22:155-63. Mukherjee KK, et al. 2012. Indian J Med Res. 136:54-9.
Gene ID: 3440
UniProt: View information about IFN-alpha2 on UniProt.org
Clone: W20057G
Regulatory Status: RUO
Other Names: IFN-alpha 2B, IFN-alphaA, IFNA2, IFNA2B
Isotype: Rat IgG2a, κ